Theracle is developing an implantable device to enable direct, targeted drug delivery to the brain for the
treatment of glioblastoma multiforme (GBM), an aggressive and lethal brain cancer with an average survival of just
15 months. To date, drug delivery to the brain has been constrained by the blood-brain barrier and dose-limiting
toxicities from IV or oral drugs. By enabling a new drug delivery modality, the Theracle device has the potential
to revolutionize treatment of GBM and improve clinical outcomes.
Our technology was developed at InCube Labs, a life science R&D lab founded by prolific healthcare innovator and
entrepreneur, Mir Imran, in partnership with Dr. Jeffrey Bruce, a neurosurgeon at Columbia University Medical
Center. We are actively exploring partnerships and collaborations with companies developing novel drugs for the
treatment of GBM.